Clearstead Advisors’s BRAINSTORM CELL THERAPUTC BCLI Stock Holding History

Clearstead Advisors’s Portfolio BCLI Stock Details BCLI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-100	Closed	-$112	–	3105
2025 Q2	$112	Hold	100	–	–	﹤0.01%	2608
2025 Q1	$126	Hold	100	–	–	﹤0.01%	2138
2024 Q4	$227	Hold	100	–	–	﹤0.01%	2029
2024 Q3	$346	Hold	100	–	–	﹤0.01%	1976
2024 Q2	$508	Hold	100	–	–	﹤0.01%	1933
2024 Q1	$822	Buy	+100	New	+$550	﹤0.01%	1421

Other funds holding BCLI

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

BSB

Bangor Savings Bank Bangor, Maine $1.36B AUM 19.29% 1-Year Est. Return

VWA

VSM Wealth Advisory Hunt Valley, Maryland $335M AUM 16.18% 1-Year Est. Return

SPIA

Steward Partners Investment Advisory New York $19.6B AUM 22.89% 1-Year Est. Return

DJSG

D.J. St. Germain Springfield, Massachusetts $2.53B AUM 17.43% 1-Year Est. Return

Clearstead Advisors's BCLI Position: Q3 2025 in Review

Clearstead Advisors sold out of BRAINSTORM CELL THERAPUTC (BCLI) in Q3 2025, closing a stake of 100 shares — an estimated $112 sold.

Clearstead Advisors first reported a position in BCLI in Q1 2024 and held it in 6 quarters. The position peaked at $822 in Q1 2024. 5 funds tracked by Wall St. Rank hold BCLI as of Q3 2025.

Clearstead Advisors reported no remaining BRAINSTORM CELL THERAPUTC position as of Q3 2025 after selling out during the quarter.
Clearstead Advisors sold 100 BRAINSTORM CELL THERAPUTC shares in Q3 2025, an estimated $112.
Clearstead Advisors first reported a position in BRAINSTORM CELL THERAPUTC in Q1 2024 and held it in 6 quarters.
Clearstead Advisors's BRAINSTORM CELL THERAPUTC position peaked at $822 in Q1 2024.
5 funds tracked by Wall St. Rank held BRAINSTORM CELL THERAPUTC as of Q3 2025.

Based on Clearstead Advisors's 13F filing for Q3 2025, filed 10 Nov 2025.